公开(公告)号：US20220306573A1

公开(公告)日：2022-09-29

申请号：US17046752

申请日：2019-04-11

Applicant: Jason Jingxi ZHANG ,  Chandra VARGEESE ,  Naoki IWAMOTO ,  Chikdu Shakti SHIVALILA ,  Nayantara KOTHARI ,  Ann Fiegen DURBIN ,  Selvi RAMASAMY ,  Pachamuthu KANDASAMY ,  Jayakanthan KUMARASAMY ,  Gopal Reddy BOMMINENI ,  Subramanian MARAPPAN ,  Sethumadhavan DIVAKARAMENON ,  David Charles Donnel BUTLER ,  Genliang LU ,  Hailin YANG ,  Mamoru SHIMIZU ,  Prashant MONIAN ,  WAVE LIFE SCIENCES LTD.

Inventor： Jason Jingxin Zhang ,  Chandra Vargeese ,  Naoki Iwamoto ,  Chikdu Shakti Shivalila ,  Nayantara Kothari ,  Ann Fiegen Durbin ,  Selvi Ramasamy ,  Pachamuthu Kandasamy ,  Jayakanthan Kumarasamy ,  Gopal Reddy Bommineni ,  Subramanian Marappan ,  Sethumadhavan Divakaramenon ,  David Charles Donnell Butler ,  Genliang Lu ,  Hailin Yang ,  Mamoru Shimizu ,  Prashant Monian

IPC: C07C317/28 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113

Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.

公开(公告)号：US20170056510A1

公开(公告)日：2017-03-02

申请号：US14917387

申请日：2016-03-08

Applicant: Dinesh U. Chimmanamada ,  Weiwen Ying ,  Junyi Zhang ,  Teresa Kowalczyk-Przewloka ,  Jun Jiang ,  Sami Osman ,  Genliang Lu ,  Dharma Vutukuri ,  James Loch ,  Shoujun Chen

Inventor： Dinesh U. Chimmanamada ,  Weiwen Ying ,  Junyi Zhang ,  Teresa Kowalczyk-Przewloka ,  Jun Jiang ,  Sami Osman ,  Genliang Lu ,  Dharma Vutukuri ,  James Loch ,  Shoujun Chen

IPC: A61K47/48 ,  A61K31/454 ,  A61K31/519 ,  A61K31/513 ,  A61K31/4184 ,  A61K31/167 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/704 ,  A61K31/497 ,  A61K31/42 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/506 ,  A61K31/565 ,  A61K38/05 ,  A61K31/4745

Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

公开(公告)号：US20230203087A1

公开(公告)日：2023-06-29

申请号：US17926987

申请日：2021-05-24

Applicant: Pachamuthu Kandasamy ,  Jayakanthan Kumarasamy ,  Chandra Vargeese ,  Subramanian Marappan ,  Gopal Bommineni ,  Mamoru Shimizu ,  Naoki Iwamoto ,  Stephany Standley ,  Yuanjing Liu ,  Amy Jada Andreucci ,  Genliang LU ,  Onanong Chivatakarn ,  Akbar Husain Khan ,  WAVE LIFE SCIENCES LTD.

Inventor： Pachamuthu Kandasamy ,  Jayakanthan Kumarasamy ,  Chandra Vargeese ,  Subramanian Marappan ,  Gopal Reddy Bommineni ,  Mamoru Shimizu ,  Naoki Iwamoto ,  Stephany Michelle Standley ,  Yuanjing Liu ,  Amy Jada Andreucci ,  Genliang Lu ,  Onanong Chivatakarn ,  Akbar Husain Khan

IPC: C07H21/04 ,  C07F9/165 ,  C07D295/02

CPC classification number: C07H21/04 ,  C07F9/165 ,  C07D295/02

Abstract: The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.

公开(公告)号：US08877970B2

公开(公告)日：2014-11-04

申请号：US12350894

申请日：2009-01-08

Applicant: Craig Zimmerman ,  John W. Babich ,  John Joyal ,  Genliang Lu ,  Kevin P. Maresca ,  Chris Barone

Inventor： Craig Zimmerman ,  John W. Babich ,  John Joyal ,  Genliang Lu ,  Kevin P. Maresca ,  Chris Barone

IPC: C07C311/15 ,  A61K49/00 ,  A61K31/555 ,  A61K51/04 ,  A61K31/444 ,  A61K31/4192 ,  A61K31/18

CPC classification number: A61K51/0406 ,  A61K31/18 ,  A61K31/4192 ,  A61K31/444 ,  A61K31/555 ,  A61K51/0446 ,  A61K51/0453 ,  A61K51/0455 ,  A61K51/0459 ,  A61K51/0474 ,  C07C311/37 ,  C07C335/16 ,  C07C335/20 ,  C07D213/36 ,  C07D249/04 ,  C07D285/135 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:

Abstract translation: 可用于CA-IX过表达特征的疾病的诊断成像和治疗性治疗的新型放射性药物包含含有能够结合CA-IX的活性催化位点的磺酰胺部分和适于放射成像的放射性核素的复合物， /或放疗：

公开(公告)号：US08211402B2

公开(公告)日：2012-07-03

申请号：US12631343

申请日：2009-12-04

Applicant: John W. Babich ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  Genliang Lu ,  Shawn Hillier

Inventor： John W. Babich ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  Genliang Lu ,  Shawn Hillier

IPC: A61K51/04 ,  A61K31/444 ,  A61K31/555 ,  A61K49/00 ,  C07D401/12 ,  C07F13/00 ,  A61P35/00

CPC classification number: C07D213/38 ,  A61K51/0478 ,  C07C311/16 ,  C07F13/005

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract translation: 识别和结合CA-IX蛋白质的化合物具有式I，II，III或IV。 化合物可以包括用于放射成像或治疗应用的放射性元件。 因此，药物组合物可以用一种或多种式I，II，III或IV的化合物制备。

公开(公告)号：US07666864B2

公开(公告)日：2010-02-23

申请号：US12411220

申请日：2009-03-25

Applicant: Charles Z. Ding ,  Genliang Lu ,  Keith Combrink ,  Dianjun D. Chen ,  Minsoo Song ,  Jiancheng Wang ,  Zhenkun Ma ,  Brian Desmond Palmer ,  Adrian Blaser ,  Andrew M. Thompson ,  Iveta Kmentova ,  Hamish Scott Sutherland ,  William Alexander Denny

Inventor： Charles Z. Ding ,  Genliang Lu ,  Keith Combrink ,  Dianjun D. Chen ,  Minsoo Song ,  Jiancheng Wang ,  Zhenkun Ma ,  Brian Desmond Palmer ,  Adrian Blaser ,  Andrew M. Thompson ,  Iveta Kmentova ,  Hamish Scott Sutherland ,  William Alexander Denny

IPC: C07D498/04 ,  A61K31/424 ,  A61K31/5365 ,  A61K31/553

CPC classification number: C07D498/04

Abstract: The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.

Abstract translation: 本发明提供了一系列双环硝基咪唑取代的苯基恶唑烷酮，其中双环硝基咪唑药效团与苯基恶唑烷酮共价键合，其药物组合物，以及组合物用于预防和治疗细菌感染的方法。 双环硝基咪唑取代的苯基恶唑烷酮对于野生型和抗性病原体菌株具有惊人的抗菌活性，因此可用于预防，控制和治疗由这些病原体引起的许多人和兽医细菌感染如结核分枝杆菌 。

公开(公告)号：US20190249173A1

公开(公告)日：2019-08-15

申请号：US16098658

申请日：2017-05-03

Applicant: Chandra VARGEESE ,  Jason Jingxin ZHANG ,  Sethumadhavan DIVAKARAMENON ,  David Charles Donnell BUTLER ,  Genliang LU ,  Naoki IWAMOTO ,  Hailin YANG ,  Maria David FRANK-KAMENETSKY ,  Subramanian MARAPPAN ,  WAVE LIFE SCIENCES LTD.

Inventor： Chandra Vargeese ,  Jason Jingxin Zhang ,  Sethumadhavan Divakaramenon ,  David Charles Donnell Butler ,  Genliang Lu ,  Naoki Iwamoto ,  Hailin Yang ,  Maria David Frank-Kamenetsky ,  Subramanian Marappan

IPC: C12N15/11 ,  A61K31/7088 ,  A61K47/54

CPC classification number: C12N15/111 ,  A61K31/7088 ,  A61K47/542 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/3515 ,  C12N2320/32

Abstract: In some embodiments, the present disclosure pertains to compositions and methods related to delivery of a biologically active agent, wherein the compositions comprise a biologically active agent and a lipid. In various embodiments, the lipid is selected from: lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, docosa-hexaenoic acid (cis-DHA), turbinaric acid and dilinoleyl. In some embodiments, a composition and method are useful for delivery of a biologically active agent to a particular cell or tissue, e.g., a muscle cell or tissue.

公开(公告)号：US08211401B2

公开(公告)日：2012-07-03

申请号：US12631337

申请日：2009-12-04

Applicant: John W. Babich ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  Genliang Lu ,  Shawn Hillier

Inventor： John W. Babich ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  Genliang Lu ,  Shawn Hillier

IPC: A61K51/04 ,  A61K31/555 ,  A61K49/00 ,  C07D403/12 ,  C07D401/12 ,  C07D213/56 ,  C07F13/00 ,  A61P25/18 ,  A61P29/00 ,  A61P13/08 ,  A61P35/00

CPC classification number: C07D213/38 ,  A61K31/18 ,  A61K31/4192 ,  A61K31/444 ,  A61K31/555 ,  A61K51/0406 ,  A61K51/041 ,  A61K51/0474 ,  A61K51/0478 ,  C07C275/16 ,  C07C311/16 ,  C07D403/06 ,  C07D403/12 ,  C07F13/005

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract translation: 式I的化合物，其药学上可接受的盐或溶剂化物：与金属如铼，锝等复合，以提供用于成像组织或治疗疾病的复合物，特别是在金属是放射性的情况下。 这种复合物对PSMA蛋白质是特异性的，因此可用于成像或治疗前列腺癌和表达蛋白质的其他组织的癌症。

公开(公告)号：US20100183509A1

公开(公告)日：2010-07-22

申请号：US12631312

申请日：2009-12-04

Applicant: John W. BABICH ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  John Marquis ,  Genliang Lu ,  Jian-cheng Wang ,  Shawn Hillier

Inventor： John W. BABICH ,  Craig Zimmerman ,  John Joyal ,  Kevin P. Maresca ,  John Marquis ,  Genliang Lu ,  Jian-cheng Wang ,  Shawn Hillier

IPC: A61K51/04 ,  C07D403/12 ,  C07F13/00 ,  A61P1/00

CPC classification number: A61K31/18 ,  A61K31/4192 ,  A61K31/444 ,  A61K31/555 ,  A61K47/22 ,  A61K49/00 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/041 ,  A61K51/0446 ,  A61K51/0474 ,  A61K51/0478 ,  C07C275/16 ,  C07C311/16 ,  C07D213/38 ,  C07D403/06 ,  C07D403/12 ,  C07F13/005

Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.

Abstract translation: 基于具有取代的吡啶基和咪唑基的配体制备杂环放射性核素的配合物。 配体是双功能的，具有可以作为生物活性分子的连接体的氨基酸残基，以及可能使该放射性核素复合的三齿螯合剂。 生物活性分子可以是肽或生长抑素。

公开(公告)号：US20090175794A1

公开(公告)日：2009-07-09

申请号：US12350894

申请日：2009-01-08

Applicant: Craig Zimmerman ,  John W. Babich ,  John Joyal ,  Genliang Lu ,  Kevin P. Maresca ,  Chris Barone

Inventor： Craig Zimmerman ,  John W. Babich ,  John Joyal ,  Genliang Lu ,  Kevin P. Maresca ,  Chris Barone

IPC: A61K49/00 ,  C07F15/00 ,  A61K31/555 ,  A61P35/00

CPC classification number: A61K51/0406 ,  A61K31/18 ,  A61K31/4192 ,  A61K31/444 ,  A61K31/555 ,  A61K51/0446 ,  A61K51/0453 ,  A61K51/0455 ,  A61K51/0459 ,  A61K51/0474 ,  C07C311/37 ,  C07C335/16 ,  C07C335/20 ,  C07D213/36 ,  C07D249/04 ,  C07D285/135 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:

Abstract translation: 可用于CA-IX过表达特征的疾病的诊断成像和治疗性治疗的新型放射性药物包含含有能够结合CA-IX的活性催化位点的磺酰胺部分和适于放射成像的放射性核素的复合物， /或放疗：